Related Experiment Video
Updated: Aug 18, 2026
A Pre-Clinical Porcine Model of Orthotopic Heart Transplantation
Published on: April 27, 2019
Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years
Jon A Kobashigawa1, Jonathan M Tobis, Randall C Starling
1University of California at Los Angeles, Los Angeles, California, USA. jonk@mednet.ucla.edu
Insights
First-year intravascular ultrasound (IVUS) showing intimal thickening over 0.5 mm predicts poor outcomes after heart transplantation. This early detection of cardiac allograft vasculopathy (CAV) serves as a reliable surrogate marker for long-term graft survival.
Area of Science:
- Cardiology
- Transplantation Medicine
- Medical Imaging
Background:
- Cardiac allograft vasculopathy (CAV) significantly impacts long-term heart transplant graft survival.
- Intravascular ultrasound (IVUS) detects intimal thickening, an early sign of CAV, more sensitively than coronary angiography.
- Previous single-center studies indicated potential for early IVUS findings to predict long-term outcomes.
Purpose of the Study:
- To evaluate the validity of first-year intravascular ultrasound (IVUS) data as a surrogate marker for long-term outcomes in heart transplant recipients.
- To determine if early intimal thickening detected by IVUS can predict adverse events and graft survival post-transplantation.
Main Methods:
- A multicenter review of 125 heart transplant recipients' first-year IVUS results and five-year clinical follow-up data.
- Core laboratory re-analysis of IVUS tapes to measure the change in maximal intimal thickness (MIT) from baseline to one year.
- Classification of patients into two groups based on MIT progression (>0.5 mm vs. <0.5 mm).
Main Results:
- Patients with >/=0.5 mm MIT progression (Group 1) had significantly higher rates of death or graft loss (20.8% vs. 5.9%, p=0.007) compared to Group 2.
- Group 1 also experienced more nonfatal major adverse cardiac events and/or death/graft loss (45.8% vs. 16.8%, p=0.003).
- Newly occurring angiographic luminal irregularities were more frequent in Group 1 (65.2% vs. 32.6%, p=0.004).
Conclusions:
- First-year intimal thickening progression of >/=0.5 mm via IVUS is a reliable surrogate marker for long-term outcomes after heart transplantation.
- This finding predicts subsequent mortality, nonfatal adverse cardiac events, and angiographic CAV development up to five years post-transplant.
- The study supports the use of early IVUS assessment for risk stratification in heart transplant recipients.
Objectives:
We sought to assess the validity of first-year intravascular ultrasound (IVUS) data as a surrogate marker for long-term outcome after heart transplantation.
Background:
Cardiac allograft vasculopathy (CAV) is a major impediment to long-term graft survival. Intravascular ultrasound is more sensitive than coronary angiography and detects intimal thickening (early CAV) in the coronary arteries of the donor heart. Single-center studies have suggested first-year IVUS results might be a surrogate marker for long-term outcome.
Methods:
First-year IVUS results and subsequent five-year clinical follow-up data were reviewed in 125 heart transplant recipients from five institutions. The IVUS tapes (at baseline and one year) were re-analyzed at a core IVUS laboratory. The change in maximal intimal thickness (MIT) from baseline to one year was recorded for several matched sites in the same coronary artery. Patients were classified into two groups: those with >/=0.5 mm in the MIT in any matched site (group 1) and those with MIT <0.5 mm (group 2).
Results:
Group 1 patients compared with group 2 patients had a higher incidence of death or graft loss (D/GL, 20.8% vs. 5.9%; p = 0.007), had more nonfatal major adverse cardiac events and/or D/GL (45.8% vs. 16.8%; p = 0.003), and had more findings of newly occurring angiographic luminal irregularities (65.2% vs. 32.6%, p = 0.004).
Conclusions:
This multicenter study suggests that progression of intimal thickening >/=0.5 mm in the first year after transplantation appears to be a reliable surrogate marker for subsequent mortality, nonfatal major adverse cardiac events, and development of angiographic CAV through five years after heart transplantation.
